Stocks
UnitedHealth Group's Mixed Q2 Report Bolstered by Bullish Outlook
UnitedHealth Group (UNH) has been underperforming compared to the S&P 500, but its attractive valuation and solid fundamentals make it a buy, according to recent analysis.
The company's Q2 results included an earnings triple play: beating revenue and EPS estimates, while also raising FY 2026 guidance. The medical loss ratio remained steady at 86.7%.
Consensus EPS upgrades and a 6.9% FCF yield support confidence in UNH's long-term growth trajectory. Technicals are mixed, with a primary bullish trend but potential for a downside move if UNH breaks below $370, potentially targeting $320.